The fourth quarter was a busy time at the US Food and Drug Administration (FDA), with a slew of approvals, including the first bispecific antibody and two drugs approved on the same day for idiopathic pulmonary fibrosis, a previously untreatable disease. Breakthrough drug designations now number 60, with more than a dozen getting through to approval. The first quarter, though, looks to be a quiet one at the FDA, although the European Medicines Agency (EMA) will be looking at some novel cell therapies.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline: 4Q14. Nat Biotechnol 33, 124 (2015). https://doi.org/10.1038/nbt.3143
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3143
